NCT02008968 is a NA clinical trial of allopurinol 300 mg./day in Hyperuricemia, sponsored by Istanbul Medeniyet University.

Who is sponsoring NCT02008968?

NCT02008968 is sponsored by Istanbul Medeniyet University.

What drugs are being tested in NCT02008968?

Interventions in NCT02008968: allopurinol 300 mg./day, No intervention, Normouricemic.

What condition does NCT02008968 study?

NCT02008968 studies Hyperuricemia, Prediabetes, Insulin Resistance.

Is NCT02008968 still recruiting?

NCT02008968 is currently status unknown. Last updated 10 December 2013.

Last reviewed 2013-12-10 · How we verify

NCT02008968

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Allopurinol Treatment on Insulin Resistance

Status unknown NA Last updated 10 December 2013

What this trial tests

NA trial testing allopurinol 300 mg./day in Hyperuricemia in 130 participants. Status unknown.

Timeline

1 December 2013

Primary endpoint
1 July 2014

1 August 2014

Quick facts

Lead sponsor	Istanbul Medeniyet University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	130
Start date	1 December 2013
Primary completion	1 July 2014
Estimated completion	1 August 2014
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

allopurinol 300 mg./day — full drug profile →
No intervention
Normouricemic — full drug profile →

Conditions studied

Hyperuricemia — all drugs for Hyperuricemia →
Prediabetes — all drugs for Prediabetes →
Insulin Resistance — all drugs for Insulin Resistance →

Sponsor

Istanbul Medeniyet University

Who can join

Adults 30 to 70, any sex, with Hyperuricemia or Prediabetes. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change in insulin resistance (HOMA-IR)
Time frame: baseline and 3 months

Sponsor's own description

Several studies showed that hyperuricemia is an independent risk factor for development of diabetes mellitus. However none of the previous studies have investigated the effect of lowering serum uric acid levels on insulin resistance of which is also named as prediabetes. With this background in mind, we aimed to test the effect of lowering serum uric acid level with allopurinol on insulin resistance.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hyperuricemia

Currently open trials in the same condition.

NCT07144332 — This Study is to Estimate the Efficacy of Hemodialysis Alone for Uric Acid Clearance in Patients on Hemodialysis. In Ord · recruiting
NCT07400549 — Prospective Exploratory Study on the Comprehensive Application Effectiveness of Exercise Prescription Decision Support T · NA · recruiting
NCT06859073 — A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia · Phase 1 · recruiting
NCT06463561 — CPAP Effect on Lipid Profile and Hyperuricemia in Patients With Dyslipidemia and Moderate-severe Obstructive Sleep Apnea · Phase 4 · recruiting
NCT06729853 — PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function · Phase 1, PHASE2 · active not recruiting

Other Istanbul Medeniyet University trials

Trials by the same sponsor.

NCT07478380 — Transcutaneous pO₂ Monitoring in PICU · recruiting
NCT07368244 — Turkish Translation and Content Validity of the Nottwil Environmental Factors Inventory (NEFI) in Persons With Spinal Co · recruiting
NCT07179731 — Comparison of the Effects of External Oblique Intercostal Plane Block, Subcostal Transverse Abdominis Plane Block, and T · NA · not yet recruiting
NCT07241455 — Validity of the Children's Chelsea Critical Care Physical Assessment Tool (cCPAx-TR) in Turkish Pediatric Intensive Care · completed
NCT07426497 — Osteopathic Manual Therapy vs Ganglion Impar Block for Chronic Coccydynia · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02008968 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Istanbul Medeniyet University
Last refreshed: 10 December 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02008968.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing